PHARM.AS Pharming Group Euronext intraday 05 Feb 2026: Volume 30.32M signals

PHARM.AS stock is trading at €1.46 intraday on 05 Feb 2026 with heavy volume of 30,320,040 shares, making it one of Europe’s most active names today. The move follows Pharming’s Investor Day and 2026 guidance for US$405–425 million revenue, driving renewed trader attention on Euronext. We track price action, technicals, valuation, and the latest guidance to explain why PHARM.AS stock sits among the most active ticks this session.

PHARM.AS stock intraday drivers

Volume is the main driver for PHARM.AS stock today. The share count of 30,320,040 is above the average 18,978,757, showing elevated liquidity and attention. Pharming’s investor update on 03 Feb 2026 guided revenue and highlighted leniolisib and napazimone development, which traders interpreted as growth confirmation. Read the company release source.

Price action and technicals

PHARM.AS trades between €1.45 and €1.55 intraday, with a previous close of €1.455. Short-term indicators show strength: RSI 71.76 (overbought) and MACD histogram 0.01. Bollinger upper band sits at €1.55, and ATR is €0.05, suggesting tight volatility in the current move. The technicals point to momentum, but overbought readings warn of pullback risk.

Fundamentals, valuation and sector context

Pharming operates in Healthcare, Biotechnology and reports cash-generating growth from Ruconest and Joenja. Key ratios: price-to-sales 3.25, price-to-book 4.27, and trailing EPS -0.01. The company shows a strong current ratio 3.16 and free cash flow yield 4.48%. Compared with the broader European Healthcare sector, PHARM.AS has higher PB than the sector average 2.79 and a lower net margin profile. That mix fits a growth-at-a-price profile.

Meyka AI rates PHARM.AS with a score out of 100

Meyka AI rates PHARM.AS with a score out of 100: 64.60 / 100 — Grade B — Suggestion: HOLD. This grade factors S&P 500 and sector benchmarks, financial growth, key metrics, forecasts, and analyst consensus. The company rating from 04 Feb 2026 shows a B- with mixed signals across DCF, ROE and PE metrics. These inputs weigh into a cautious hold stance.

Meyka AI forecast, price targets and outlook

Meyka AI’s forecast model projects a 12‑month value at €1.99, a three-year target of €3.16, and a five-year target of €4.32. Versus the current price €1.46, the 12‑month projection implies upside of 36.30%. Forecasts are model-based projections and not guarantees. For trading, set a base target €1.99, a bullish target €3.16, and a conservative downside buffer near €1.10 for risk management.

Catalysts, risks and trading summary

Near-term catalysts include upcoming pipeline readouts and the March earnings date on 12 Mar 2026. The Investor Day materials and expert panels support longer-term opportunity in PIDs and mtDNA programs. External coverage has mixed views, with some analysts highlighting a shift to profitability. Key risks are execution on clinical trials, regulatory timelines, and valuation pressure if revenue growth slows. Traders should note high intraday liquidity and a relVolume of 1.07, enabling position sizing and exits.

Final Thoughts

PHARM.AS stock is one of the most active European names in this intraday session, trading at €1.46 on Euronext with 30,320,040 shares changing hands. The immediate cause is a combination of guidance and Investor Day detail on leniolisib and napazimone, which underpin the company’s 2026 revenue view. Technicals show momentum but overbought signals, so intraday traders should manage stop levels. Meyka AI’s forecast model projects €1.99 for the next year, an implied upside of 36.30% versus today’s price. Our Meyka grade is 64.60 / 100 (B, HOLD), reflecting solid cash flow and pipeline potential offset by rich book multiples and clinical execution risk. For active traders, the stock’s high volume gives clear entry and exit opportunities. Long-term investors should watch the 2026 trial data and the March earnings release before changing core exposure. For live levels and alerts see our Meyka AI-powered market analysis page for PHARM.AS Meyka PHARM.AS page. For company guidance and Investor Day materials see the Pharming release source.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.